Trevena reports Q1 EPS (36c) vs (81c) last year

Reports Q1 revenue $20,000 vs $0 last year. “TRV045 clinical development continued to progress in the first quarter, and we believe its novel MOA, once daily, oral dosing and favorable tolerability profile, has the potential to address the significant unmet need for non-opioid therapies in pain and for novel mechanisms in epilepsy,” said Carrie Bourdow, President and CEO of Trevena.